Genomic profiling has unveiled the molecular subtypes and mutational landscape of pancreatic ductal adenocarcinoma (PDAC). However, there is a knowledge gap on the consistency of gene expression across PDAC tumors profiled in independent studies and this limits follow up research. To facilitate novel drug target prioritization and biomarker discovery, we investigated the most consistently expressed genes in human PDAC. We identified ~4,000 genes highly or lowly expressed in at least 4 of 5 microarrays (adjusted P<0.05) and validated their expression pattern in additional datasets, bulk tumor and single-cell RNA sequencing samples. Over 50% of the genes were previously uncharacterized in PDAC; many correlated with proliferation, metastasis, mutation, tumor grade, and ~41% predicted overall survival. We identified 185 high-priority targets (notably in cell cycle and glycolysis) whose inhibition suppressed PDAC cell viability in multiple RNA interference datasets and these genes predicted treatment in mouse models. Our results represent important milestone in the quest for mechanisms, drug targets and biomarkers in PDAC, and originate from an adaptable analytical concept that can aid discovery in other cancers.
Pancreatic ductal adenocarcinoma (PDAC) is highly metastatic and drug resistant and is one of the most lethal solid malignancies. Genomic profiling studies have defined the molecular subtypes and mutational landscape of PDAC and extensive gene expression profiling dataset have been accumulated to date. However, there is a knowledge gap on the consistency of gene expression across profiled PDAC samples and this limits the prospects of clinical translation. To facilitate novel drug target prioritization and biomarker discovery, we have extensively analyzed over 20 publicly accessible datasets. We report the most consistently expressed genes in PDAC tissues compared to non-tumors. Specifically, we identified 3,938 consistent genes, including 2,010 consistently upregulated genes, topmost of which included LAMC2, TMPRSS4, S100P, SLC6A14, COL10A1, CTSE, LAMB3, CEACAM5/6, and glucose transporter SLC2A1, and 1,928 consistently downregulated genes top among which include AOX1, IAPP, albumin (ALB), SERPINI2, PDK4 and PNLIPRP1/2 (adjusted P<0.05). Over 50% of the genes are unknown. In addition, these genes largely reflected the same expression pattern in bulk and single cell RNA sequencing analysis, showed tumors-specificity, and correlated with several cancer indices including proliferation, metastasis, mutation and tumor grade. Pathway enrichment analyses revealed ‘pathways in cancer', ‘focal adhesion', ‘p53', ‘cell cycle', ‘transcription factor binding', “glycolysis” among upregulated processes. These pathway alterations were accompanied by profound metabolic alterations and signatures of disrupted pancreatic homeostasis. Interactome and disease ontology analyses further linked the consistent genes with precancerous conditions, PDAC, and malignancy. We found that ~41% of the genes predicted patients' overall survival in at least two datasets while clustering analyses and receiver operating characteristic analysis uncovered highly probable biomarkers. Subsequent analysis of gene silencing datasets identified 185 ‘high-priority' genes (notably candidates in cell cycle and glycolysis) whose knockdown suppress PDAC viability. Our multi-dimensional analysis is an important milestone in the quest for mechanisms, drug targets and biomarkers in PDAC, and outlines an adaptable analytical approach that can aid biomarker or therapeutic target discovery in other cancers. Citation Format: Zeribe Chike Nwosu, Heather C. Giza, Verodia Charlestin, Maya Nassif, Daeho Kim, Samantha Kemp, Nina G. Steele, Costas A. Lyssiotis, Marina Pasca di Magliano. Identification of high priority genes for basic and translational pancreatic cancer research [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr NG02.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.